CClinicalTrials.gg
CompletedNCT04063774Updated Aug 21, 2019

Clinical Trial of Diagnostic Tests and Clinical Algorithms for Dengue in Febrile Subjects in Endemic Areas in Colombia

An interventional study of Dengue calculator in Dengue, sponsored by Lyda Osorio. Completed at 3 sites in Colombia. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by Lyda Osorio · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Dec 2016, registered Aug 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
1,045
Allocation
Not applicable
01

Study summary

The present study aimed to develop a sensitive dengue diagnostic clinical algorithm using the resources that are available at the health care institutions, clinical expertise, and identification of signs and symptoms and variables of the hemogram associated with dengue. The performance of the potential algorithms were assessed under routine care. A single group cuasiexperimental study with a Bayesian adaptive design was conducted. Prior and cumulative information was used during intermediate analysis of clinical algorithms performance and according to these results algorithms were modified and then implemented in the subsequent study subjects. Men and women of all ages, seeking care due to fever of less than 15 days were recruited in 3 endemic areas in Colombia. The algorithms were applied by study physicians and blood samples taken for hemogram and dengue reference tests. It was planned that algorithms with high sensitivity (95%) and specificity (80%) were implemented in real life to assess their impact on patients outcomes alone and in combination with dengue rapid diagnostic tests but this was not feasible as not algorithms achieved the targetted performance. The experience of physicians using the algorithm in a mobile device was going to be explored with qualitative methods but this was explored with study physicians.

02

Conditions studied

  • Dengue

Browse trials for

Keywords

  • diagnostics
  • sensitivity
  • specificity
  • clinical algorithm
03

In context

Dengue

279 studies on the registry are indexed under Dengue; 45 are open to participants now.

This study's enrollment of 1,045 is above the median of 123 across 195 interventional studies indexed under Dengue.

Browse Dengue studies →

Lead sponsor

This is the only study on the registry with Lyda Osorio as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Accepts healthy volunteers
No

Inclusion criteria

  • Fever of less than 15 days

Exclusion criteria

Exclusion Criteria:

  • Origin of fever identified
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,045 participants (actual)

Study arms

  • Experimental
    Dengue diagnostic algorithm

    single arm of consecutive enrolled subjects with fever in whom the dengue diagnostic algorithms were applied by study physician and blood sample taken for hemogram and dengue reference tests (gold standard)

    Diagnostic Test: Dengue calculator

Interventions

  • Diagnostic testDengue calculator

    Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device

06

What researchers measure

Primary outcomes

  1. Sensitivity of dengue calculator

    Number of correctly identified dengue cases by intervention out of all laboratory confirmed dengue cases

    Time frame: 0 days

  2. Specificity of dengue calculator

    Number of correctly identified non-dengue cases by intervention out of all laboratory confirmed non-dengue cases

    Time frame: 0 days

Secondary outcomes

  1. Sensitivity in dengue and probable dengue cases

    Number of correctly identified dengue cases by intervention out of all laboratory confirmed plus probable dengue cases

    Time frame: 0 days

07

Study locations

3 sites
  • Hospital Regional de la Orinoquía
    Yopal, Casanare, Colombia
  • Clinica y Hospital Local de Piedecuesta
    Piedecuesta, Santander, Colombia
  • COMFANDI Torres y Alameda
    Cali, Valle Del Cauca 760045, Colombia
08

References and documents

Individual participant data

Plan to share: Yes — Patient unidentifiable data and detailed algorithms available upon request

Supporting information: Study protocol, Sap, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04063774
Lead sponsor
Lyda Osorio
Collaborators
COMFANDI CAJA DE COMPENSACION DEL VALLE DEL CAUCA, SISTEMA GENERAL DE REGALIAS CASANARE, SANTANDER VALLE DEL CAUCA, RED AEDES
Responsible party
Lyda Osorio (Professor, Universidad del Valle, Colombia) — Sponsor-investigator
First posted
Aug 21, 2019
Start date
Dec 27, 2016
Primary completion
Jul 15, 2018
Completion
Jul 15, 2018
Last update
Aug 21, 2019

Study contacts

Lyda Osorio, MD PhD
principal investigator · Universidad del Valle
Diana Ma Caicedo, MD MSc
principal investigator · Universidad del Valle

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion